Thursday, 18 September 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 18 September 2025
News

CSL moves on first-in-class hopeful

Posted 17 September 2025 AM

CSL has signed a development agreement for a potential first-in-class blood drug, and nabbed the option to purchase the whole company if it is especially pleased with the trial results.

Privately-held Dutch company VarmX signed the deal with CSL for VMX-C001, a potential first-in-class recombinant Factor X protein administered as a rapid single-dose, intended to counter dangerous effects of patients taking FXa inhibitors as chronic anticoagulation therapy.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (25)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (6)

Devices (1)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.